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Lipid rafts are enriched in cholesterol and sphingomyelin and are isolated on the basis of insolubility in
detergents, such as Brij 98 and Triton X-100. Recent work by Holm et al. has shown that rafts insoluble in Brig
98 can be found in human immunodeficiency virus type 1 (HIV-1) virus-like particles, although it is not known
whether raft-like structures are present in authentic HIV-1 and it is unclear whether a virion-associated
raft-like structure is required for HIV replication. Independently, it was previously reported that virion-
associated cholesterol is critical for HIV-1 infectivity, although the specific requirement of virion cholesterol
in HIV-1 was not examined. In the present study, we have demonstrated that infectious wild-type HIV-1
contains Brij 98 rafts but only minimal amounts of Triton X-100 rafts. To directly assess the functional
requirement of virion-associated rafts and various features of cholesterol on HIV-1 replication, we replaced
virion cholesterol with exogenous cholesterol analogues that have demonstrated either raft-promoting or
-inhibiting capacity in model membranes. We observed that variable concentrations of exogenous analogues
are required to replace a defined amount of virion-associated cholesterol, showing that structurally diverse
cholesterol analogues have various affinities toward HIV-1. We found that replacement of 50% of virion
cholesterol with these exogenous cholesterol analogues did not eliminate the presence of Brij 98 rafts in HIV-1.
However, the infectivity levels of the lipid-modified HIV-1s directly correlate with the raft-promoting capacities
of these cholesterol analogues. Our data provide the first direct assessment of virion-associated Brij 98 rafts
in retroviral replication and illustrate the importance of the raft-promoting property of virion-associated
cholesterol in HIV-1 replication.
Lipid rafts are ordered plasma membrane (PM) subdomains
that have high levels of cholesterol, sphingomyelin, and glyco-
phospholipids compared to the overall membrane (5, 6, 56).
Lipid rafts are isolated from the cell on the basis of their
cholesterol-dependent insolubility in cold detergent (6, 7, 53),
which is a direct consequence of the physical association of
sphingomyelin and cholesterol (5, 55, 57). Recently, lipid rafts
obtained with different detergents have been shown to vary
extensively in their protein and lipid contents (53). Lipid rafts
have been implicated as important for the replication of hu-
man immunodeficiency virus type 1 (HIV-1) (8, 23, 33, 39, 41,
48, 64). The precise role of lipid rafts in HIV-1 replication is,
however, unknown. In particular, it is unclear how virion-as-
sociated lipids, such as cholesterol, contribute to HIV-1 infec-
tivity and whether the HIV-1 lipids must be in a raft-like
arrangement in the virion. While recent work has shown that
rafts insoluble in Brij 98 can be found in HIV-1 virus-like
particles (VLPs) (23), the presence of raft-like structures in
wild-type (WT) HIV-1 has not been determined. A number of
other enveloped viruses also rely on cholesterol-rich lipid rafts
to support their replication (3, 25, 34, 35, 37, 52, 60), and it is
unclear whether these different viral pathogens share a similar
mechanistic requirement of cholesterol to support their repli-
cation.
During HIV-1 assembly, viral proteins are transported from
the cytoplasm to the PM for budding. The translocation of
membrane-associated HIV-1 Gag complexes to membrane
rafts is thought to be driven by the multimerization of Gag via
its interacting domains (33, 41). These membrane raft struc-
tures exhibit properties that are distinct from those of classical
rafts (13, 33), and the term “barges” was coined to reflect their
altered flotation properties during raft isolation (33). The no-
table lack of raft markers and the detergent insolubility after
cholesterol removal reinforce the notion that these Gag com-
plexes are distinct from classical Triton X-100 (Triton) rafts
(13). In contrast to Gag, the viral envelope proteins (Env) are
directly targeted to PM lipid rafts by palmitoylation of the
cytoplasmic domain of Env (48). The difference between the
route of raft association of Env and that of Gag may play a
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subtle role in virion assembly and release from specific PM raft
environments, although Gag is known to associate efficiently
with rafts (13, 23, 33, 41) and undergo viral budding in the
absence of Env expression (18, 24).
As WT HIV-1 buds from an infected cell, it incorporates
host cell raft molecules (such as Thy-1, GM1, CD14, CD48,
CD55, and CD59) (39, 42) yet excludes the nonraft membrane
protein CD45 (39), supporting the notion that HIV-1 particles
are released from lipid rafts. The HIV-1 lipid envelope be-
comes enriched in cholesterol and sphingomyelin (2), a phe-
nomenon that is most probably attributable to the high con-
centrations of these lipids in rafts (6, 56). The enrichment of
cholesterol and incorporation of raft proteins into HIV-1,
while highly suggestive, does not prove that a Brij 98 raft-like
lipid arrangement is present in the HIV-1 envelope, nor
whether such a structure is required for the subsequent infec-
tion of target cells. Like HIV-1, fowl plague virus (FPV), ve-
sicular stomatitis virus, and Semliki Forest virus are enveloped
viruses with cholesterol-enriched viral membranes (30, 36, 47,
51). In comparison with the virion membranes of vesicular
stomatitis virus and Semliki Forest virus, which do not contain
Triton rafts, cholesterol within the viral envelope of FPV is
strongly associated with the virion particle, and the FPV en-
velope contains Triton raft-like structures (51).
During HIV-1 entry, gp120 Env binds CD4 and undergoes a
conformational change that promotes the binding of gp120
Env to cell surface coreceptors (29). In the event of fusion
between HIV-1 and the target cell membrane, the pretrans-
membrane region of gp41 Env protein is thought to aggregate
on the virion surface and expose a fusion-active peptide do-
main, which facilitates virion entry into the target cell (4). The
conformational rearrangement of the viral fusion peptide
draws the viral and cellular lipid bilayers into close proximity
and leads to the formation of the hemifusion stalk and the
eventual creation of the fusion pore (10, 14). It is conceivable
that virion-associated lipid may play an active role in the re-
arrangement of the viral envelope proteins to facilitate virion
fusion.
In assessing the functional role of virion-associated Brij 98
rafts and structural features of cholesterol on HIV-1 replica-
tion, we replaced virion-associated cholesterol with exogenous
cholesterol analogues that have demonstrated raft-promoting
or -inhibiting properties and measured the resultant virion
particle density and viral infectivity. We found that replace-
ment of virion-associated cholesterol with these exogenous
cholesterol analogues did not eliminate the presence of Brij 98
raft-like structures in HIV-1. However, we show that HIV-1
infection directly correlates with the raft-promoting capacity of
the sterol analogues. Our findings highlight the importance of
the HIV-1 lipid composition for viral infectivity and suggest
that the raft-promoting property of virion-associated choles-
terol is an important contributor to viral function.
MATERIALS AND METHODS
Virus production. WT HIV-1 particles were produced via calcium phosphate
transfection of 293T cells as previously described (9, 22, 54). Cells were main-
tained in Dulbecco’s modified Eagle’s medium (Gibco/BRL, Gaithersburg, Md.)
containing 10% heat-inactivated fetal calf serum (P.A. Biologicals Co., Mel-
bourne, Australia), 100 U of penicillin/ml, and 100 g of streptomycin/ml. Cells
were transfected with 10 g of HIV-1 proviral DNA (pNL-4.3) (1) or 10 g of
HIV-1 luciferase reporter proviral DNA pNL4-3.Luc.R-E- (11) (obtained from
the AIDS Reagent Program, National Institute of Allergy and Infectious Dis-
eases, National Institutes of Health, from N. Landau) and 5 g of the HIV-1
envelope, Vpr and Nef expression vector pNLA1 (gift of D. Purcell, University
of Melbourne), as previously described (9).
Methyl--cyclodextrin (CD) treatment of HIV-1. Viral particles were purified
from the supernatant and concentrated by ultracentrifugation through 20%
sucrose, by using an L-90 ultracentrifuge (SW28 rotor; Beckman, Fullerton,
Calif.) at 93,000  g for 1 h at 4°C. Virus pellets were eluted in phosphate-
buffered saline (PBS). CD preferentially removes cholesterol over phospholipids
(28). Concentrated virus was treated with 0.5 mM CD (Sigma, St. Louis, Mo.) in
PBS at 37°C for 1 h to remove cholesterol from the HIV-1 lipid envelope as
previously described (9).
Cholesterol and cholesterol analogue replenishment of CD-treated HIV-1.
4-Cholestenone (4-cholesten-3-one), cholesterol (cholest-5-en-3-ol), coprosta-
nol (5-cholestan-3-ol), 7-dehydrocholesterol (5,7-cholestadien-3-ol), and di-
hydrocholesterol (5-cholestan-3-ol) were obtained from Sigma. 3-Epicholes-
terol was obtained from Steraloids (Newport, R.I.). The exchange of virion-
associated cholesterol with exogenous cholesterol requires the initial removal of
cholesterol from the HIV-1 particle by CD and the subsequent replenishment of
the cholesterol-depleted virus with exogenous cholesterol or cholesterol ana-
logues. Briefly, 1.3 g of p24 capsid (CA) equivalent concentrated virus was
treated with 0.5 mM CD for 1 h at 37°C. This step was followed by the addition
of a 12, 25, 50, or 100 M concentration of exogenous cholesterol or cholesterol
analogue to the CD and virus suspension in a total volume of 400 l for another
1 h of incubation at 37°C. As all exogenous sterols were first dissolved in ethanol
and subsequently introduced to CD-treated HIV-1, the same amounts of ethanol
were added to the mock- and CD-treated HIV-1 without sterol replenishment as
the control.
Sucrose equilibrium density gradient analysis. To examine alterations to the
viral particle buoyant density induced by lipid modification of the virus structure,
we employed 30 to 55% sucrose (Gibco/BRL) density gradients prepared in
2.5% increments as previously described (9). Untreated, CD-treated, and cho-
lesterol analogue-replenished HIV-1 preparations were layered onto separate
gradients and centrifuged for 16 h at 87,000  g (SW41 rotor; L-90 ultracentri-
fuge; Beckman). Fractions were collected from the top of the gradient and
analyzed for reverse transcriptase (RT) activity and density as previously de-
scribed (9).
Infectivity assay. To ensure the removal of free CD and CD-sterol complexes,
the peak virus-containing fractions (by RT activity) were pooled from sucrose
density gradients, diluted with PBS and repelleted through a 20% sucrose cush-
ion at 93,000  g for 1 h at 4°C. After eluting the virion pellet in 100 l of PBS,
equivalent p24 CA amounts, determined by an HIV-1 antigen (p24 CA) Micro-
ELISA assay (Vironostika; Organon Teknika, Boxtel, The Netherlands), of un-
treated and cholesterol-depleted (and sterol-replenished) HIV-1 were used to
infect MT2 cells as previously described (9). The success of infection was deter-
mined by the level of luciferase activity in the MT2 cells by using a Luciferase
Assay System (Promega, Madison, Wis.). The impact of CD treatment and
replenishment by cholesterol or cholesterol analogues on HIV-1 infectivity is
represented as a percentage (mean  standard error [SE] for duplicate samples)
of untreated controls. The significance of the result was assessed by using Stu-
dent’s t test (two-sample unequal variance; two-tailed).
OptiPrep gradient purification. OptiPrep velocity gradient ultracentrifugation
was used to separate virion particles from soluble viral proteins, cell membrane-
derived lipid microvesicles, and other cell debris that may interfere with subse-
quent analysis. OptiPrep (60% [wt/vol] iodixanol; Sigma) gradients were pre-
pared in PBS in 1.2% increments of 6 to 18% iodixanol as previously described
(9, 12). The peak virus-containing fractions were pooled, diluted in PBS, and
repelleted through a 20% sucrose cushion for 1 h at 4°C at 93,000  g to
reconcentrate the viral particles.
Lipid analysis of virus replenished with sterol analogues. The introduction of
exogenous cholesterol and cholesterol analogues into CD-treated HIV-1 also
was assessed by qualitative lipid analysis using high-performance liquid chroma-
tography (HPLC). Virus purified on OptiPrep gradients was gently resuspended
in 1 ml of PBS containing antioxidants (33.3 M butylated hydroxytoluene and
33.3 mM EDTA). Sterols were extracted with 2.5 ml of methanol and 5 ml of
hexane (16, 17). The solvent for the hexane phase was evaporated, and the
sample was added to 200 l of the mobile phase (44% acetonitrile, 54% 2-pro-
panol, 2% water). For HPLC analysis of cholesterol and epicholesterol or 4-cho-
lestenone, we used the mobile phase containing 97.5% n-hexane and 2.5%
2-propanol, while cholesterol and 7-dehydrocholesterol were better separated
when 0.5% acetonitrile was added. These compounds were detected at 210 nm.
Cholesterol and coprostanol or dihydrocholesterol were also separated with a
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mobile phase of 97.5% n-hexane and 2.5% 2-propanol, but an evaporative light
scattering detector was used for detection. Peak area was used for quantification
and was compared to known quantities of cholesterol or cholesterol analogues.
Flotation experiments. WT HIV-1, CD-treated HIV-1, and HIV-1 particles
replenished with 7-dehydrocholesterol, dihydrocholesterol, coprostanol, or
4-cholestenone were purified on an OptiPrep gradient and gently resuspended in
1 ml of cold raft lysis buffer (containing either 0.5% Triton [for WT HIV-1 and
293T cells only] or 0.5% Brij 98 and 1 mM EDTA, 1 mM sodium orthovanadate,
1 mM phenylmethylsulfonyl fluoride, 10 g of aprotinin/ml, 150 mM sodium
chloride, and 25 mM MES [4-morpholineethanesulfonic acid; pH 6.5]). The
Triton viral lysates were incubated on ice for 30 min, whereas the Brij 98 viral
lysates were incubated at 37°C for 5 min. Simultaneously, 107 uninfected 293T
cells were washed twice in PBS and resuspended in 1 ml of raft lysis buffer. 293T
cells were subjected to flotation analysis to ensure that our experimental condi-
tions were capable of producing detergent-resistant lipid rafts from normal cell
membranes. The virion lysate and the control cell lysate were then subjected to
10 strokes in a Dounce homogenizer. The homogenates were adjusted to 45%
sucrose by the addition of 1 ml of 90% sucrose in MES-buffered saline (25 mM
MES, 150 mM NaCl) and placed at the bottom of a 12-ml SW41 ultracentrifuge
tube. A gradient was formed above the lysate by layering 2 ml (each) of 35, 30,
25, and 5% sucrose in MES-buffered saline. After ultracentrifugation at 150,000
 g for 16 h at 4°C (SW41 rotor; L-90 ultracentrifuge; Beckman), 10 1-ml
fractions were collected from the top of the gradient. Proteins in the gradient
fractions were precipitated with 10% trichloroacetic acid and analyzed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by
immunoblotting for gp41 Env in the virion gradient fractions and for caveolin
protein (an integral raft marker) (15, 31) in the WT virion gradient fractions and
the 293T cell gradient fractions.
Immunoblotting. Equal volumes of WT HIV-1 flotation gradient fraction
samples were subjected to immunoblotting for gp41 Env to detect flotation of
lipid raft-like membranes to regions of lower buoyancy in the gradient and for
p24 CA to monitor the fractionation of nonraft proteins as previously described
(9). To determine if gp120 Env protein levels were unchanged by lipid modifi-
cation of the viral particle, virion lysates were standardized for p24 CA content
and then analyzed for gp120 Env content as previously described (9). Membranes
of the 293T cell control flotation gradient samples and WT HIV-1 Brij 98 raft
gradient fraction samples were probed overnight at 4°C with anti-caveolin poly-
clonal antibodies (raised in rabbit; Transduction Laboratories), followed by
secondary antibody conjugated to horseradish peroxidase. Specific proteins were
visualized by enhanced chemiluminescence according to manufacturer’s instruc-
tions (Amersham Pharmacia Biotech; Little Chalfont, Buckinghamshire, En-
gland).
RESULTS
Triton rafts have been implicated in the assembly and bud-
ding processes of various enveloped viruses, including HIV-1
(33, 39, 41, 44, 48, 60, 63). However, the presence of a raft
within the infectious HIV-1 viral membrane has not been dem-
onstrated. With Env-deficient HIV-1 VLPs, Holm et al. have
detected Brij 98 rafts, but not Triton rafts (23), suggesting that
a Brij 98 raft-like structure may be found in infectious HIV-1.
WT HIV-1 particles contain Brij 98 lipid rafts. WT HIV-1
particles purified via an OptiPrep gradient were subjected to
lipid raft isolation (see Materials and Methods). OptiPrep gra-
dient purification removes contaminating microvesicles (lipid
micelles derived from the virus-producing cell membrane) that
may interfere with the interpretation of results (12). To ensure
that the lipid raft isolation gradient was floating raft mem-
branes, Triton-treated 293T cells were subjected to the flota-
tion analysis and probed for caveolin (a resident raft protein)
in the gradient fractions (15, 31). Fractions 3 and 4 have most
of the caveolin-containing floating material (Fig. 1, lanes 3 and
4), indicating the lipid raft region of the gradient being used.
Purified HIV-1 particles were treated with the detergent Brij
98 or Triton, and flotation gradient analysis was performed.
We found that WT HIV-1 particles package raft-associated
caveolin, and that44% of the total virion-associated caveolin
floated to the raft region of the gradient following treatment of
WT HIV-1 with 0.5% Brij 98 (Fig. 1, lanes 2 to 4). As the
HIV-1 transmembrane protein gp41 Env is anchored to the
lipid bilayer of the virion, we used gp41 Env as the virion
membrane marker. We found that 15% of the total virion
gp41 Env floated to the raft region of the gradient (Fig. 1, lanes
2 to 4) when purified HIV-1 was treated with 0.5% Brij 98. In
contrast, less than 6% of the total virion gp41 Env can be
detected in the raft fractions when purified HIV-1 was treated
with 0.5% Triton (Fig. 1, lanes 2 to 4). These data demonstrate
the presence of a detergent-resistant structure in the HIV-1
membrane, which is more resistant to Brij 98 than Triton. The
exclusive presence of p24 CA in the soluble fractions indicates
that the virion particle was fully solubilized by the Brij 98
detergent.
Since the use of detergents as a method for the character-
ization of lipid raft formation is indirect and may be subject to
artifacts (53) and also does not reveal the functional require-
ment of Brij 98 rafts in virion particles, we pursued a comple-
mentary approach by using our cholesterol replacement system
to assess whether sterols that disrupt or promote lipid raft
formation contribute to HIV-1 replication. Using a model
membrane system, Xu and London have observed that 4-cho-
lestenone and coprostanol inhibit the formation of lipid raft-
like structures (62), while cholesterol, 7-dehydrocholesterol,
dihydrocholesterol, and, to a lesser extent, epicholesterol sup-
port the formation of these structures (61, 62). It was previ-
ously proposed that the incorporation of lipid raft-disrupting
sterol analogues into the HIV-1 particle decreases viral infec-
tivity, while lipid raft-promoting analogues support viral infec-
tivity (9). The replacement of virion cholesterol in CD-treated
HIV-1 with exogenous cholesterol restores viral infectivity and
buoyant particle density to that of WT HIV-1 (9). For this
FIG. 1. WT HIV-1 particles were analyzed for lipid raft-like do-
mains. WT HIV-1 particles purified on OptiPrep gradients were
treated with 0.5% Brij 98 or Triton detergent and subjected to sucrose
flotation gradient analysis (see Materials and Methods). Fractions 1 to
10 (lanes 1 to 10) were taken from the top of the gradient. 293T cells
were used as the positive control for successful Triton raft isolation,
with caveolin-containing raft membranes floating to fractions 3 and 4
(n  5). Viral proteins were precipitated from each fraction and
analyzed by SDS-PAGE and immunoblotting for raft-resident caveolin
protein and p24 (in the Brij 98 raft gradient) and for viral gp41
envelope proteins (in both the Brij 98 and Triton raft gradients). Data
are representative of the results of two experiments.
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study, we used buoyant density (1.149 g/ml) as an indirect
marker to monitor the restoration of WT HIV-1 structure after
sterol analogue replacement.
Cholesterol analogues with modifications in the fused A,B
rings are readily incorporated into CD-modified HIV-1. The
density gradient sedimentation profiles of CD-treated HIV-1
containing various cholesterol analogues were compared. The
sterol analogues used in this study have modifications in either
the 3-hydroxyl group or the fused A,B ring structure (Fig. 2).
At least four different concentrations (12, 25, 50, and 100 M)
of exogenous sterol analogue were used during the replenish-
ment of CD-treated virions. With a 100 M concentration of
exogenous analogue supplied to CD-treated HIV-1, the buoy-
ant density of the CD-treated HIV-1 was either restored to or
fell below the WT level (Fig. 3). The 3-hydroxyl group of
analogue-replenished particles supplied with a 100 M con-
centration of exogenous analogue shifted the buoyant density
of the CD-treated HIV-1 to within the WT level (Fig. 3B and
C), whereas the fused A,B ring analogues supplied with exog-
enous analogue at the same concentration shifted the buoyant
densities of the replenished CD-treated particles to well below
that of WT HIV-1 (Fig. 3D to F). It was previously shown that
the buoyant densities of lipid-modified HIV-1 shift below that
of the WT when excess exogenous cholesterol was supplied to
CD-treated HIV-1 (Fig. 3A) (9). These data suggest that the
assorted cholesterol analogues used in this study (Fig. 2) ex-
hibit different affinities toward the CD-treated virion particle.
CD-treated virion particles containing exogenous choles-
terol analogues and displaying WT virion buoyant density were
chosen to directly compare the impact of different features of
cholesterol on HIV-1 function. Epicholesterol (25 M), 4-cho-
lestenone (50 M), 7-dehydrocholesterol (25 M), dihydro-
cholesterol (12 M), and coprostanol (12 M) were used to
restore the buoyant density of CD-treated HIV-1 to the WT
level, and these are denoted as “low ” sterol concentrations as
shown in Fig. 3. The incorporation of exogenous cholesterol
analogues into CD-treated HIV-1 particles was independently
confirmed by HPLC analysis of the sterol contents of the par-
ticles (Table 1). We found that all CD-treated HIV-1 that was
incubated with the low concentrations of sterols contained
exogenously supplied analogue, which represents roughly 50%
of the total virion sterol content.
Brij 98 rafts are present in CD-treated HIV-1 replenished
with raft-promoting and -inhibiting sterol analogues. To de-
termine the effect of replacing HIV-1 virion cholesterol with
50% sterol analogue (Table 1) on the presence of detergent-
insoluble membrane structures in the viral envelope, we sub-
jected lipid-modified particles purified on OptiPrep gradients
to treatment with 0.5% Brij 98 followed by lipid raft isolation
(see Materials and Methods). We found that Brij 98 rafts, as
indicated by the proportion of gp41 Env detected in the raft
region as a percentage of the total gp41 Env loaded on the
gradient, were present in each of the sterol replenishment
conditions tested and in CD-treated HIV-1 (Fig. 4), indicating
that cholesterol-depleted virions maintain Brij 98 resistance. In
comparison to the untreated WT HIV-1, in which15% of the
total gp41 Env forms Brij 98 raft membranes (Fig. 1), the
replacement of 50% of virion-associated cholesterol with
raft-promoting sterol analogues 7-dehydrocholesterol and di-
hydrocholesterol results in Brij 98 raft formation in 27% and
26% of the total gp41 Env, respectively. This finding suggests
that these raft-promoting analogues have a stronger associa-
tion with Brij 98 rafts in the virion lipid membrane than native
cholesterol molecules, consistent with the higher affinity of
these analogues toward CD-treated HIV-1. In comparison,
replacement of 50% of virion cholesterol with the raft-dis-
rupting sterol analogues 4-cholestenone and coprostanol pro-
duced Brij 98 rafts in 18% of the total gp41 Env in both
cases. Compared to the 26 to 27% level of Brij 98 rafts
produced by the raft-promoting analogues, the 18% level of
Brij 98 rafts present within the particles replenished with raft-
disrupting analogues is in agreement with the respective raft-
promoting and -disrupting properties of these analogues in
model membranes.
It is important to note that the percentage of gp41 Env
protein in the Brij 98 rafts of WT HIV-1 virions (15%) (Fig.
FIG. 2. Structures of sterols used in the present report. Variation in
the 3-hydroxyl group (A) or A,B ring structure (B) of cholesterol is
shown. Conventional numerical labeling of the carbon atoms and al-
phabetical labeling of the four rings are indicated for cholesterol.
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1) is not significantly different from the percentage of Brij 98
rafts in HIV-1 modified with raft-disrupting analogues (18%)
(Fig. 4). This discrepancy may result in part from the notions
that (i) a Brij 98 raft-like structure may still exist in the virion,
as only 50% of virion-associated cholesterol was replaced with
exogenous sterol analogue, and (ii) various sterol analogues
have different affinities toward lipid-modified HIV-1 that can
potentially influence the levels of detectable virion Brij 98 rafts
after detergent solubilization. By definition, the insolubility of
proteins after detergent solubilization is an in vitro phenome-
non, which may adversely alter the interpretation of the results
(19). Furthermore, this manner of Brij 98 raft isolation does
not provide specific information on the arrangement of lipid on
the virion surface or the effects of these sterols on viral infec-
tivity.
The 3-hydroxyl group of virion-associated cholesterol is
critical for viral infectivity. Previously, we used our virion
replacement system to integrate an oxidized form of choles-
terol, 5-cholestenone, into HIV-1 and observed a reduction in
viral infectivity, suggesting that the 3-hydroxyl group of cho-
lesterol is critical for HIV-1 infectivity (9). In order to further
evaluate the importance of the 3-hydroxyl group of choles-
terol in HIV-1 replication, we have replaced virion-associated
cholesterol with 4-cholestenone and epicholesterol (Fig. 2).
We show that the supplementation of CD-treated HIV-1 with
4-cholestenone (a natural product of cholesterol oxidase) at
concentrations of between 12 and 100 M inhibits viral infec-
tivity (Fig. 5E), in agreement with the previous finding that the
oxidative state of the 3-hydroxyl group of cholesterol contrib-
utes to HIV-1 infectivity. When 50% of HIV-1 virion choles-
FIG. 3. Density gradient profiles of lipid-modified HIV-1 where exogenous cholesterol or analogues with modification in the 3-hydroxyl group
(A to C) or with alterations in the A,B ring structure (D to F) were used. WT HIV-1 was mock-treated, CD-treated (0.5 mM), or CD-treated and
incubated with exogenous cholesterol, epicholesterol, or 4-cholestenone. RT activity was detected in density gradients (A to C) of untreated (),
CD-treated (E), and CD-treated HIV-1 that had subsequently been replenished with a low concentration (‚) or a 100 M concentration (ƒ) of
exogenous sterol. CD-treated HIV-1 was replenished with low concentrations of exogenous sterols as follows: 25 M cholesterol (A), 25 M
epicholesterol (B), 50 M 4-cholestenone (C), 25 M 7-dehydrocholesterol (D), 12 M dihydrocholesterol (E), and 12 M coprostanol (F). The
duplicate percentage of total RT activity data points varied by 	3% (the SE). Data are representative of three experiments. Corresponding
densities (broken line) of each fraction (A) were determined by refractivity index measurements, where duplicate measurements varied by 0.001
g/ml (the SE).
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terol was replaced with 4-cholestenone (exogenously supplied
at a concentration of 50 M), the lipid-modified HIV-1 dis-
plays a significant decrease in viral infectivity (20% of the WT
level).
To assess the importance of the configuration of cholesterol
at C3 and its impact on viral function, we replaced 50% of
virion-associated cholesterol with exogenous epicholesterol
(Fig. 2) by using 0.5 mM CD and 25 M epicholesterol. Epi-
cholesterol differs from cholesterol in that its 3-OH group has
a different chirality than cholesterol. In contrast to the level of
infectivity restored by exogenous cholesterol (Fig. 5A), the
supplementation of CD-treated HIV-1 with epicholesterol par-
tially restored viral infectivity in a variable range of 45 to 80%
(Fig. 5C), but the result was not significantly different from that
with the cholesterol-replenished CD-treated HIV-1 particles
with WT density. Of all the sterol analogues used to replace
the virion-associated cholesterol of CD-treated HIV-1, epicho-
lesterol displayed significant variation in its capacity to restore
viral infectivity, with its 80% infectivity being the best restora-
tion that we have detected. It is worth noting that the raft-
promoting capacity of epicholesterol in a model membrane
system is also found between raft-promoting and raft-inhibit-
ing analogues, such as dihydrocholesterol and coprostanol, re-
spectively, at the physiological temperature of 37°C (62).
The fused A,B rings in cholesterol are an important deter-
minant of viral infectivity. We next replaced virion-associated
cholesterol with 7-dehydrocholesterol, coprostanol, or dihy-
drocholesterol (Fig. 3D to F; Table 1) to assess the impact of
the sterol analogues on viral infectivity. 7-Dehydrocholesterol
differs from cholesterol as it has an additional double bond
between C7 and C8 of the B ring, giving the sterol molecule a
higher oxidative state and reducing the flexibility in the B ring
of the molecule (Fig. 2). In contrast, coprostanol and dihydro-
cholesterol are the reduced forms of cholesterol, exhibiting a
lower overall oxidative state at C5 and C6. Coprostanol and
dihydrocholesterol differ from each other only in their chirality
at C5, which causes the sterol A ring to be positioned differ-
ently in relation to the B ring of cholesterol. The incubation of
CD-treated virus with 25 M 7-dehydrocholesterol, 12 M
dihydrocholesterol, or 12 M coprostanol produced viral par-
ticles of WT buoyant density (Fig. 3D to F). The replacement
of 50% of the HIV-1 virion cholesterol (Table 1) with either
7-dehydrocholesterol or dihydrocholesterol did not reduce the
infectivity of HIV-1 (Fig. 5B and D). In contrast, replacing
40% of virion-cholesterol with coprostanol (Table 1) re-
sulted in virion particles with 30% of WT HIV-1 infectivity
(Fig. 5F). These findings suggest that the fused ring structure
of virion-associated cholesterol has a role in HIV-1 infectivity.
Excess cholesterol analogues reduce infectivity. It has been
shown previously that the incubation of CD-treated HIV-1
with increasing concentrations of exogenous cholesterol will
lead to the eventual suppression of HIV-1 infectivity (9).
This high-dose cholesterol-suppressive activity for CD-treated
HIV-1 is also detected for the sterol analogues 7-dehydrocho-
lesterol, epicholesterol, 4-cholestenone, and coprostanol (Fig.
5B, C, E, and F), supporting the notion that only a finite
amount of sterol can be accommodated by the HIV-1 virion
before impairing viral infectivity (9). Similarly, for the CD-
FIG. 4. Brij 98 raft analysis of CD-treated HIV-1 replenished with
raft-promoting and raft-disrupting sterol analogues. Concentrated
HIV-1 particles were treated with CD and replenished with exogenous
sterol analogues in the following concentrations: 25 M 7-dehydro-
cholesterol, 12 M dihydrocholesterol, 50 M 4-cholestenone, and 12
M coprostanol. Modified HIV-1 particles were purified by OptiPrep
gradients, treated with 0.5% Brij 98 detergent, and subjected to su-
crose flotation gradient analysis (see Materials and Methods). Frac-
tions 1 to 10 (lanes 1 to 10) were taken from the top of the gradient.
CD-treated HIV-1 was included as a control for Brij 98 detergent
resistance. Viral proteins were precipitated from each fraction and
analyzed by SDS-PAGE and immunoblotting for viral gp41 envelope
proteins (n  2). Quantification of protein bands was performed by
using Image Gauge version 3.3 software and is represented in fractions
2 to 4 (the floating membrane region) as a percentage of the total
protein loaded on the gradient (n  2; SE, 6%).
TABLE 1. Proportions of cholesterol to sterol analogue in lipid-modified HIV-1a
Treatment group
Concn (g/mg of p24) of: Sterol levels vs
control (%)
Cholesterol:
cholesterol
analogue
No.
individual
expts
Mean buoyant
density
(g/ml)Cholesterol Cholesterol analogue Total sterol
Control 2.14 (0.17) NA 2.14 (0.17) 100 NA 4 1.149 (0.001)
CD (0.5 mM) 1.23 (0.22) NA 1.23 (0.22) 57 NA 4 1.157 (0.001)
CD  replenishment with:
Cholesterol 3.45 (0.45) NA 3.45 (0.45) 161 NA 4 1.145 (0.004)
Epicholesterol 1.49 (0.15) 1.00 (0.20) 2.49 (0.34) 116 60:40 3 1.149 (0.001)
4-Cholestenone 0.91 (0.40) 1.54 (0.89) 2.45 (0.52) 115 37:63 3 1.149 (0.001)
7-Dehydrocholesterol 0.99 (0.28) 1.13 (0.13) 2.12 (0.37) 99 47:53 3 1.149 (0.001)
Dihydrocholesterol 1.18 (0.14) 1.22 (0.34) 2.40 (0.45) 112 49:51 4 1.151 (0.005)
Coprostanol 1.91 (0.33) 1.29 (0.28) 3.20 (0.37) 150 60:40 4 1.151 (0.004)
a Standard deviations of the means are given in parentheses. NA, not applicable.
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treated particles supplied with a 100 M concentration of
cholesterol or dihydrocholesterol, we detected reduced infec-
tivity compared to viruses that were incubated with the same
analogues at the lower concentration of 50 M (Fig. 5A and
D). This result indicates that an excess of raft-promoting an-
alogues, when supplied to the CD-treated HIV-1 at a high
concentration, will also suppress viral infectivity.
It is important to note that CD treatment of HIV-1 is a
prerequisite for adjusting the buoyant particle density and viral
infectivity by modifying the virion-associated cholesterol con-
tent. In the absence of CD, the sterol analogues do not alter
the peak density fraction or HIV-1 infectivity from the WT
control level (Fig. 6).
Maintenance of gp120 envelope protein levels after replac-
ing virion cholesterol with sterol analogues. HIV-1 particles
lacking viral envelope proteins are unable to infect target cells.
It has previously been shown that CD-treated HIV-1 (9, 21)
and CD-treated HIV-1 replenished with 5-cholestenone (9) do
not affect the anchoring of HIV-1 gp120 Env protein on the
virion particles. However, it remains possible that the decrease
in HIV-1 infectivity observed upon replacement of virion cho-
lesterol with the sterol analogues 4-cholestenone and copros-
FIG. 5. Viral infectivity of lipid-modified HIV-1. HIV-1 containing
the luciferase reporter gene was mock treated, CD treated (0.5 mM), or
CD treated and incubated with exogenous cholesterol (A), 7-dehydrocho-
lesterol (B), epicholesterol (C), dihydrocholesterol (D), 4-cholestenone
(E), or coprostanol (F). Lipid envelope-modified and untreated HIV-1
were normalized for p24 capsid protein content and used to infect MT2
cells. The levels of luciferase activity were used as the indicator of infec-
tivity levels, which are reported as percentages (means SE of duplicate
samples) of the untreated control. Infectivity levels of untreated (a), CD-
treated (b), and CD-treated HIV-1 that has subsequently been incubated
with a 12 (c), 25 (d), 50 (e), or 100 (f) M concentration of exogenous
sterol are shown. Filled bars represent replenished virions that exhibited
WT particle density profiles (same as the low replenishment described in
legends for Fig. 2 and 3). P values were 0.01, 0.2, 0.1, 	0.01, and 0.01,
respectively, for filled bars in panels B, C, D, E, and F; n  4. Data are
representative of three experiments. *, epicholesterol-replenished parti-
cles of WT density exhibited an infectivity range of 45 to 80%.
FIG. 6. Density gradient profiles and infectivity levels of HIV-1
supplemented with sterol analogues in the absence of CD. WT HIV-1
was mock-treated or incubated with exogenous sterol analogues in the
absence of CD (see Fig. 2). RT activity detected in density gradients
(A) of untreated HIV-1 () or HIV-1 incubated in 100 M concen-
trations of epicholesterol (E), 4-cholestenone (‚), coprostanol (ƒ),
dihydrocholesterol ({), or 7-dehydrocholesterol (). Duplicate per-
centages for total RT activity data points varied by 	3% (the SE).
HIV-1 containing the luciferase reporter gene was mock treated (B,
bar a) or incubated with 100 M concentrations of epicholesterol (bar
b), 4-cholestenone (bar c), coprostanol (bar d), dihydrocholesterol
(bar e), or 7-dehydrocholesterol (bar f). All samples were normalized
for p24 capsid protein content and used to infect MT2 cells. The levels
of luciferase activity were used as indicators of infectivity levels, which
are reported as percentages (means  SE of duplicate samples) of the
untreated control. Data are representative of two to three experiments.
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tanol may arise in part from the interference with the anchor-
ing of the envelope protein to the virion lipid bilayer. In order
to test this theory, we analyzed the levels of gp120 envelope
proteins in HIV-1 particles that have modifications in their
virion lipid envelopes (Fig. 7). Similar to previous findings (9),
our data show that the reduction in infectivity associated with
cholesterol depletion or sterol analogue replenishment of CD-
treated HIV-1 cannot be attributed to a reduction in HIV-1
envelope proteins on the virion surface.
DISCUSSION
The WT HIV-1 lipid envelope contains Brij 98 rafts. Raft
extraction detergents have different selectivities in their dis-
ruption of lipid-protein interactions and their enrichment of
cholesterol and sphingolipids over glycerophospholipids (53).
Schuck et al. (53) found that the selectivity for detergent-
insoluble membranes is greater for Triton than for Brij 98,
which correlates with results with these two detergents for the
types of detergent-resistant membranes we isolated from the
HIV-1 viral membrane. Our findings are in agreement with
those of Holm et al. (23), who showed that Brij 98 rafts, but not
classical Triton rafts, are found in Env-deficient HIV-1 VLPs.
We then examined the role of virion Brij 98 rafts in HIV-1
replication.
The raft-promoting property of sterols is required for HIV-1
infectivity. In this study, we have shown that the replacement
of 50% of the HIV-1 cholesterol with the raft-inhibiting sterol
analogues 4-cholestenone or coprostanol (62) suppresses
HIV-1 infectivity, while the replacement of 50% of HIV-1
cholesterol with the raft-promoting sterol analogues 7-dehy-
drocholesterol and dihydrocholesterol (61, 62) did not alter
viral infectivity, even though Brij 98 rafts can be isolated from
both types of lipid-modified virus. It is important to note that
the inhibition of infectivity did not result from a change in the
amounts of Brij 98 rafts in the HIV-1 viral membrane or in the
levels of virion-associated envelope protein, showing that the
presence of Brij 98 rafts in HIV-1 is not sufficient to support
viral replication. Suboptimal infectivity (45 to 80% of that of
the WT control) was observed for virions containing epicho-
lesterol, a sterol analogue that partially supports raft formation
compared to cholesterol (62). The detection of Brij 98 deter-
gent-insoluble rafts in virions containing raft-disrupting sterols
suggests that our virion cholesterol replacement analysis can
detect subtle effects on the lipid arrangement that lead to
alterations in viral infectivity, but do not necessarily alter the
Brij 98 insolubility of gp41 in the viral membrane, as observed
in CD-treated HIV-1. Our data show a direct correlation be-
tween the capacity of the virion-associated sterol to support
raft formation in a model membrane system and viral infectiv-
ity (61, 62).
Cholesterol analogues and the viral lipid envelope. It has
been hypothesized that the formation of lipid rafts in cell
membranes is driven by lipid-lipid interactions such as those
between cholesterol and sphingolipid (55). For example, when
the 3-hydroxyl group of cholesterol is replaced with a ketone
group, as in 4-cholestenone, the hydrogen bond-accepting abil-
ity of the sterol is eliminated and hydrogen bonding to the
sphingolipid polar head group is abolished. The raft-promoting
sterol analogues used in this study have a molecular structure
that allows them to form ordered structures with sphingolipids,
whereas raft-inhibiting sterol analogues disrupt the ordered
packing arrangement of phospholipids and decrease mem-
brane rigidity. It is possible that the binding interactions that
occur between coprostanol or 4-cholestenone and neighboring
viral membrane molecules affect the viral membrane in a man-
ner that disrupts fusion yet maintains a detectable Brij 98-
resistant raft component. The replacement of virion choles-
terol with these selected analogues will undoubtedly alter viral
membrane rigidity, but in a range that is not differentiated by
Brij 98 raft extraction. The correlation of infectivity levels with
the incorporation of raft-promoting sterols suggests that the
increased rigidity or lipid order of the viral particle, but not the
presence of a physical Brij 98 resistant raft structure, plays a
crucial role in viral infectivity.
Contribution of virion cholesterol to HIV-1 replication. It
was previously shown that the enriched cholesterol content of
the HIV-1 particle is critical for viral infectivity and virion
stability (9). Cholesterol-depleted HIV-1 virions exhibit sup-
pressed infectivity (9, 21) through disruption of the virion lipid
bilayer (9), yet display normal levels of viral protein by immu-
noblotting, notably of gp120 Env (9, 21), and bind to the
surface CD4 receptor and coreceptor(s) of target cells (21).
The cholesterol-depleted virions, however, are not internalized
upon binding (21). The recent finding by Graham et al. (20)
showed that cholesterol removal from the HIV-1 membrane
causes virion permeabilization and further supports a role for
viral cholesterol in HIV-1 replication.
Raft-promoting sterols in HIV-1. The precise mechanistic
contribution of virion-associated cholesterol in HIV-1 replica-
tion remains undefined. Virion-associated cholesterol may fa-
cilitate the HIV-1 fusion entry process through the formation
and stabilization of the hemifusion stalk and the creation of the
fusion pore. Following CD4 and coreceptor binding, the gp41
Env entity of the HIV-1 Env complex inserts a fusion peptide
into the cell membrane (14) to draw the viral and cell mem-
branes into close proximity. The gp41 Env then snaps back
onto itself to form a helical hairpin structure that overcomes
the hydration barrier between the opposing lipid bilayers, and
membrane fusion is initiated via a hemifusion stalk intermedi-
FIG. 7. Immunoblot analysis of HIV-1 gp120 envelope proteins
and p24 CA proteins present in lipid-modified HIV-1. Concentrated
HIV-1 particles were treated with CD and replenished with exogenous
sterol analogues. Microvesicle contamination was removed by purifi-
cation on OptiPrep gradients as described in Materials and Methods.
Sample input was standardized by p24 CA content. Lane 1, untreated
HIV-1 control; lane 2, CD-treated HIV-1; lane 3, CD-treated HIV-1
replenished with cholesterol; lane 4, CD-treated HIV-1 replenished
with epicholesterol; lane 5, CD-treated HIV-1 replenished with 4-cho-
lestenone; lane 6, CD-treated HIV-1 replenished with 7-dehydrocho-
lesterol; lane 7, CD-treated HIV-1 replenished with dihydrocholes-
terol; lane 8, CD-treated HIV-1 replenished with coprostanol (n  2).
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ate (14, 38). The effect of cholesterol on membrane fusion may
represent a general course of action for the stabilization of the
fusion pore.
It is known that the lipid content of the PM can affect the
arrangement of viral envelope proteins (46, 49, 50). In the
presence of cholesterol, the pretransmembrane region of
HIV-1 gp41 Env protein favors membrane fusion, while raft-
inhibiting sterols suppress fusion (50), indicating a role for the
raft-promoting capacity of cholesterol in the fusion of mem-
branes. Furthermore, HIV-1 may contain specialized choles-
terol-rich rafts that are involved in virion permeabilization and
have a role in fusion (20). In another example, the envelope
protein of the influenza virus requires cholesterol in the target
membrane to stabilize the opening of the fusion pore. It is
important to note that cholesterol analogues that support raft
formation stabilized influenza virus-cell membrane pore for-
mation, while raft-inhibiting analogues did not (46). Although
Razinkov and Cohen assessed the role of cholesterol in the
target membrane (46), in contrast to our study of the viral
membrane, the fundamental requirement of cholesterol is its
capacity to support raft formation during fusion, which is likely
to be the same in viral and target membranes. A requirement
for cholesterol during HIV-1 fusion may represent a general
principle among other viral pathogens that require cholesterol
during entry into their respective target cells (27, 34, 43, 58).
Development of a topical microbicide that adjusts the viri-
on-associated cholesterol content. It has been suggested that
cholesterol-removing agents, such as CD, may potentially be
used as topical microbicides against HIV-1 (21, 26, 32, 40, 45,
59). Our data have revealed important clues for the develop-
ment of such a microbicide, namely: (i) CD in combination
with a raft-disrupting sterol analogue further inhibits viral in-
fectivity; (ii) CD in combination with excess sterols acts to
suppress HIV-1 infection; and (iii) sterols with high affinity for
the HIV particle may lower the amount of cholesterol ana-
logue or CD required to affect the particle, thus reducing the
likelihood of cytotoxic effects. One would predict that the com-
bination of CD with a synthetic cholesterol analogue that en-
compasses these features would be invaluable for the formu-
lation of a CD-based topical microbicide against HIV-1. The
development of this new topical microbicide is likely to have
wider applications in preventing the transmission of other sex-
ually acquired pathogens, including the herpes simplex virus
and Chlamydia.
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